The Investor's Podcast (We Study Billionaires) - The Investor’s Podcast Network

TIP857: S&P Global, Novo, Deckers Brands w/ Stig Brodersen, Tobias Carlisle, & Hari Ramachandra

20 snips
Nov 1, 2026
Stig Brodersen, investor and educator, joins value investor Tobias Carlisle and Silicon Valley investor Hari Ramachandra for three lively stock pitches. They debate Novo Nordisk’s discounted obesity franchise, S&P Global’s ratings moat and AI exposure, and Deckers Brands’ HOKA and UGG portfolio. Each thesis faces tough questions on competition, patents, fashion risk, consumer weakness, valuation, and capital allocation.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Obesity Drugs May Form A Duopoly

  • Eli Lilly’s stronger efficacy does not necessarily create a winner-take-all market because patients respond differently to compounds.
  • Novo may compete through lower cost, patient-specific responses, and a large global obesity market.
ADVICE

Study Pharma Systems Beyond Patent Cliffs

  • Analyze pharmaceutical systems, not just patent cliffs and individual products.
  • Novo’s key question is whether its pipeline can restore efficacy leadership before major expirations around 2030–2032.
INSIGHT

S&P Ratings Form A Protected Oligopoly

  • S&P Global’s ratings business benefits from an oligopoly where Moody’s and S&P complement rather than replace each other.
  • Regulation and adverse-selection economics make reputable ratings necessary for efficient bond issuance.
Get the Snipd Podcast app to discover more snips from this episode
Get the app